Overview

Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
This purpose of this study is to investigate whether the number and size of rectal polyps can be reduced in patients with Familial Adenomatous Polyposis (FAP) by using a highly-purified form of a naturally occurring substance, the omega-3 fatty acid, eicosapentaenoic acid (EPA).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
S.L.A. Pharma AG